Mohyeldin Reham H, Abdelnaser Mahmoud, Sharata Ehab E, Kotb Al Shaimaa Mahmoud, Ali Fatma F, Attya Mina Ezzat, Tawfik Heba M, Elrehany Mahmoud A, Rofaeil Remon Roshdy
Department of Pharmacology & Toxicology, Faculty of Pharmacy, Deraya University, Minia, 61111, Egypt.
Deraya Center for Scientific Research, Deraya University, Minia, 61111, Egypt.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun 4. doi: 10.1007/s00210-025-04327-0.
Gentamicin (GEN) is a commonly prescribed antibiotic for Gram-negative bacterial infections. One of the most common adverse consequences of it is renal damage which is developed in 30% of individuals receiving GEN for over 7 days. For the first time, we attempted to examine the reno-protective activity of rupatadine (RUP) on GEN-induced renal injury in rats. Renal damage was established by GEN in male Wistar rats. Histopathological analysis and kidney function panel were assessed. Levels of MDA, catalase, and SOD were detected using the colorimetric method. ELISA was utilized to assess the renal levels of IL-1β and TNF-α. qRT-PCR assessed mRNA levels of Bax and Bcl-2. Protein expression of Nrf-2, NF-κB, and caspase 3 were evaluated using Western blotting. GEN resulted in renal malfunction, high serum levels of cystatin C and BUN, increased renal levels of MDA, TNF-α, and IL-1β, decreased SOD and catalase activities, stimulated renal activation of NF-κB, and caspase 3 as well as inhibited the Nrf-2 protein expression, and upregulated Bax gene expression while it suppressed Bcl-2 gene expression. Conversely, RUP administration markedly attenuated the nephrotoxicity of GEN. RUP suppressed the levels of the proinflammatory mediators, inactivated the renal NF-κB and caspase 3 proteins, declined renal mRNA levels of Bax gene, and upregulated the renal mRNA level of the Bcl-2 gene. In conclusion, RUP mitigated GEN-caused renal damage by suppressing proinflammatory markers, mitigating apoptosis via repressing the intracellular PAF/NF-κB/caspase-3 pathway and upregulating Nrf2/HO-1 signaling cascades.
庆大霉素(GEN)是一种常用于治疗革兰氏阴性菌感染的抗生素。其最常见的不良后果之一是肾损伤,在接受GEN治疗超过7天的个体中,有30%会出现这种情况。我们首次尝试研究卢帕他定(RUP)对GEN诱导的大鼠肾损伤的肾保护活性。通过给雄性Wistar大鼠注射GEN来建立肾损伤模型。评估组织病理学分析和肾功能指标。采用比色法检测丙二醛(MDA)、过氧化氢酶和超氧化物歧化酶(SOD)的水平。利用酶联免疫吸附测定(ELISA)评估肾组织中白细胞介素-1β(IL-1β)和肿瘤坏死因子-α(TNF-α)的水平。通过定量逆转录聚合酶链反应(qRT-PCR)评估Bax和Bcl-2的mRNA水平。使用蛋白质免疫印迹法评估核因子E2相关因子2(Nrf-2)、核因子κB(NF-κB)和半胱天冬酶3的蛋白表达。GEN导致肾功能障碍、血清胱抑素C和血尿素氮水平升高、肾组织中MDA、TNF-α和IL-1β水平增加、SOD和过氧化氢酶活性降低、刺激肾组织中NF-κB和半胱天冬酶3的激活以及抑制Nrf-2蛋白表达,并上调Bax基因表达,同时抑制Bcl-2基因表达。相反,给予RUP可显著减轻GEN的肾毒性。RUP抑制促炎介质水平,使肾组织中的NF-κB和半胱天冬酶3蛋白失活,降低肾组织中Bax基因的mRNA水平,并上调肾组织中Bcl-2基因的mRNA水平。总之,RUP通过抑制促炎标志物、通过抑制细胞内血小板活化因子/核因子κB/半胱天冬酶-3途径减轻细胞凋亡以及上调Nrf2/血红素加氧酶-1信号级联反应来减轻GEN引起的肾损伤。